Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
Apogee Therapeutics (NASDAQ: APGE) has announced its upcoming participation in the Jefferies Global Healthcare Conference. The company's management team will engage in a fireside chat scheduled for Thursday, June 5, 2025, at 10:30 a.m. ET. Interested parties can access both live and archived versions of the presentation through the News & Events page in the Investors section of Apogee's website.
Apogee Therapeutics (NASDAQ: APGE) ha annunciato la sua prossima partecipazione alla Jefferies Global Healthcare Conference. Il team di gestione della società parteciperà a una conversazione informale prevista per giovedì 5 giugno 2025, alle 10:30 a.m. ET. Gli interessati potranno accedere sia alla versione in diretta sia a quella registrata della presentazione tramite la pagina News & Eventi nella sezione Investitori del sito web di Apogee.
Apogee Therapeutics (NASDAQ: APGE) ha anunciado su próxima participación en la Conferencia Global de Salud de Jefferies. El equipo directivo de la empresa participará en una charla informal programada para el jueves 5 de junio de 2025, a las 10:30 a.m. ET. Las personas interesadas podrán acceder tanto a la versión en vivo como a la archivada de la presentación a través de la página de Noticias y Eventos en la sección de Inversores del sitio web de Apogee.
Apogee Therapeutics (NASDAQ: APGE)가 Jefferies 글로벌 헬스케어 컨퍼런스에 곧 참가할 예정임을 발표했습니다. 회사 경영진은 2025년 6월 5일 목요일 오전 10:30 ET에 예정된 파이어사이드 채팅에 참여할 예정입니다. 관심 있는 분들은 Apogee 웹사이트 투자자 섹션의 뉴스 및 이벤트 페이지를 통해 생중계 및 녹화된 발표를 모두 시청할 수 있습니다.
Apogee Therapeutics (NASDAQ : APGE) a annoncé sa prochaine participation à la Jefferies Global Healthcare Conference. L'équipe de direction de l'entreprise participera à une discussion informelle prévue le jeudi 5 juin 2025 à 10h30 ET. Les personnes intéressées peuvent accéder aux versions en direct et archivées de la présentation via la page Actualités & Événements dans la section Investisseurs du site web d'Apogee.
Apogee Therapeutics (NASDAQ: APGE) hat seine bevorstehende Teilnahme an der Jefferies Global Healthcare Conference angekündigt. Das Management-Team des Unternehmens wird an einem Fireside-Chat teilnehmen, der für Donnerstag, den 5. Juni 2025, um 10:30 Uhr ET geplant ist. Interessierte können sowohl die Live- als auch die aufgezeichnete Version der Präsentation über die Seite „News & Events“ im Investor-Bereich der Apogee-Website abrufen.
- None.
- None.
SAN FRANCISCO and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 10:30 a.m. E.T.
A live and archived webcast of the fireside chat will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.
About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, EoE, COPD and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit https://apogeetherapeutics.com.
Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
noel.kurdi@apogeetherapeutics.com
Media Contact:
Dan Budwick
1AB
dan@1abmedia.com
